Hong Kong Insurance Stock News

Generally speaking long term investing is the way to go. But no-one is immune from buying too high. For example the...

HG Semiconductor Limited ( HKG:6908 ) shares have had a horrible month, losing 27% after a relatively good period...

Most readers would already be aware that China Hongqiao Group's (HKG:1378) stock increased significantly by 45% over...

PetroChina Company Limited recently reported its third-quarter and nine-month earnings results, showing that for the quarter ended September 30, 2025, sales reached CNY 719.16 billion while net income was CNY 42.29 billion, both slightly lower than the previous year. An additional development sees PetroChina proposing amendments to its governance structure, including abolishing the supervisory committee at its upcoming December 2025 EGM. We’ll explore how the recent earnings release and...

JD Logistics recently announced that its board will convene on November 13, 2025, to review and approve unaudited results for the third quarter ended September 30, 2025, while its supply chain arm JoyLogistics introduced integrated delivery and installation services for bulky items in Malaysia and Singapore. This expansion into Southeast Asia, coupled with operational updates for its key subsidiary Deppon, draws attention to both growth opportunities and ongoing challenges for JD Logistics...

Jiangsu Expressway (SEHK:177) just released its earnings for the nine months ended September 30, 2025, highlighting a dip in both revenue and net income compared to last year. This update has caught the attention of investors. See our latest analysis for Jiangsu Expressway. Jiangsu Expressway’s 1-year total shareholder return of 25.25% stands out, especially with the share price up 11.43% so far this year. While the latest nine-month results gave investors pause, solid multi-year total return...

HKBN (SEHK:1310) reported a significant turnaround in its latest results, with net profit margins rising to 1.9%, up sharply from last year’s slim 0.1%. EPS growth for the year hit an eye-catching 1912.9%, a notable reversal after five years of annual declines averaging 26%. For investors, the story is all about whether this remarkable profit rebound can deliver sustained upside, especially with earnings forecast to grow nearly 50% per year, well ahead of the broader Hong Kong market, but...

Beijing Jingneng Clean Energy (SEHK:579) posted stable earnings, with average earnings growth of 6.5% per year over the past five years and net profit margins improving from 14.4% to 14.9%. Earnings growth for the most recent year came in at 5.8%, slightly below the company’s longer-term pace. Future earnings are forecast to increase 8.43% per year and revenue is expected to grow at 3.7% per year. Investors will likely focus on the company’s steady profit and revenue performance, as well as...

Zhejiang Expressway (SEHK:576) reported revenue projected to rise by 5.5% annually, which is slower than the Hong Kong market’s expected 8.6% pace. The company’s net profit margin came in at 29%, down from 32% the previous year. This decrease reflects the impact of a one-off gain of CN¥3.2 billion in the headline figures. Earnings are forecast to grow 3.6% per year, which is slower than both its five-year average of 11.1% and the market’s 12% outlook. Investors will be focusing on the...

Beijing North Star (SEHK:588) remains unprofitable, with losses deepening at an annual rate of 61.5% over the past five years and no sign of margin recovery. The company's net profit margin has failed to improve, making any historical comparisons for earnings growth impossible at this stage. Despite the tough trends, Beijing North Star trades at a Price-to-Sales Ratio of 0.4x, which is well below peers at 8.5x and also under the Hong Kong real estate industry average of 0.7x. The current...

Central China Securities (SEHK:1375) just delivered a major earnings milestone. Net profit margins jumped to 25.5%, a surge from last year’s 9.5%. EPS growth rocketed 182.8%, vastly overshadowing its five-year average of 4.5% per year. Investors are likely to welcome the results, as the company’s valuation multiples remain lower than both sector and industry averages, supporting a rare combination of margin expansion and accelerating profit growth. See our full analysis for Central China...

China Datang Corporation Renewable Power (SEHK:1798) is guiding for earnings growth of about 19% annually, easily outpacing both the Hong Kong market’s 12% average and the expected 8.6% for market revenue. The company’s current net profit margin sits at 13.2%, a compression from last year’s 14.9%, while average annual earnings growth over the past five years has been 7.9%. With these numbers illustrating robust forward expectations but pointing to mixed margin dynamics, investors are...

Xtep International Holdings Limited recently adjusted the conversion prices of its 2021, 2024, and 2025 Convertible Bonds following the declaration and payment of its 2025 Interim Dividend, with these changes already put into effect. This move modifies the conversion terms for bondholders, which could affect future capital structure decisions and influence the investment preferences of existing and potential stakeholders. We will explore how the adjustment of convertible bond conversion...

Kinetic Development Group (SEHK:1277) has raised its stake in MC Mining to over 40% by completing its share subscriptions. This move highlights its long-term commitment to the Makhado Project in South Africa. The company now plans to push its holding toward 51%, signaling ongoing interest in MC Mining’s future growth prospects. See our latest analysis for Kinetic Development Group. Kinetic’s ongoing investment push comes as share price momentum quietly builds, with a 1-month share price...

Ascletis Pharma Inc. announced the selection of ASC36, a once-monthly subcutaneously administered amylin receptor agonist, as its next clinical development candidate for obesity, with an anticipated US FDA Investigational New Drug Application submission in the second quarter of 2026. This candidate was discovered and optimized using Ascletis' proprietary artificial intelligence-assisted drug discovery and ultra-long-acting platform technologies, emphasizing the company's innovative approach...

Hansoh Pharmaceutical Group (SEHK:3692) just announced that China’s National Medical Products Administration has accepted its New Drug Application for HS-10365 capsules, targeting RET fusion-positive non-small cell lung cancer. This regulatory milestone may draw investor attention given its pipeline implications. See our latest analysis for Hansoh Pharmaceutical Group. Hansoh Pharmaceutical Group’s latest regulatory news comes amid a year of remarkable momentum, with the share price up a huge...

BYD (SEHK:1211) reported five-year annualized earnings growth of 47.1%, while more recent annual growth sits at 13.1%. With earnings projected to climb 18.84% per year and revenue expected to increase by 12.4% annually, both outpacing Hong Kong market averages, investors are watching these growth metrics closely. Net profit margins came in at 4.6%, down a touch from last year’s 5%, reflecting ongoing pressure but leaving room for optimism about forward momentum. See our full analysis for...

China Unicom (Hong Kong) (SEHK:762) just released its latest earnings, reporting higher revenue and net income for the nine months ended September 2025 compared to last year. The company also updated investors about its growing subscriber and network numbers. See our latest analysis for China Unicom (Hong Kong). Momentum has been strong for China Unicom (Hong Kong), with its recent results reflected not just in the books, but also in investor sentiment. The company’s share price has climbed...

Kingsoft (SEHK:3888) is in the spotlight after its subsidiary Beijing Kingsoft Office Software posted strong revenue and profit gains for the first nine months of 2025. This highlights effective execution and strengthens its financial position. See our latest analysis for Kingsoft. Kingsoft’s latest numbers surface just as the company rides a wave of optimism, with software policy shifts in China providing added momentum. The share price has gained 5.81% year-to-date, but what really stands...

Postal Savings Bank of China (SEHK:1658) delivered 13.7% earnings growth this year, outpacing its longer-term profit growth of 5.1% per year over the past five years. Net profit margins climbed from 23.8% to 26.9% and shares now trade at HK$5.48, still significantly below the discounted cash flow fair value estimate of HK$9.87. Investors have seen a string of high-quality results, with ongoing revenue and profit growth driving improved profitability, even as earnings forecasts remain a touch...

AIA Group Limited recently reported a record 25% rise in its third-quarter 2025 value of new business, with double-digit growth led by Hong Kong, Mainland China, ASEAN, and India. This result was driven by a record agency value of new business and an 18% increase in recruitment, reflecting the company's strong distribution capabilities in Asian markets. We'll examine how AIA Group's record growth in new business value influences its investment outlook and long-term earnings narrative. These...

CARsgen Therapeutics Holdings recently announced encouraging results from clinical trials of its CAR-T therapies for solid tumors and plasma cell leukemia, while also commencing a share repurchase program covering up to 10% of issued share capital as mandated by its shareholders. This combination of promising clinical advancements in immuno-oncology and capital management initiatives sets the company apart in a highly competitive sector. We’ll explore how the initiation of a large share...

Innovent Biologics recently reported third quarter 2025 product revenue exceeding RMB 3.3 billion, achieving around 40% year-on-year growth driven by both oncology and newly launched biomedicine therapies, including mazdutide and SINTBILO®. The company also announced positive Phase 3 results for mazdutide, showing it surpassed semaglutide in both glycemic and weight reduction outcomes for Chinese patients with type 2 diabetes and obesity, highlighting a potential new-generation treatment...

Weichai Power (SEHK:2338) reported another year of earnings growth, with net profit margins improving to 5.3% from 5.1% and annual earnings rising by 8.8%, outpacing its five-year average of 5.6% a year. Looking ahead, forecasts point to annual earnings growth of 10.92% and revenue gains of 5.8% per year. Trading at a price-to-earnings ratio of 10.6x, which stands below both the peer average and industry levels, the stock offers investors a margin story supported by solid profitability...